Log in

Relevant bibliographies by topics / Platelet activating factor / Journal articles

To see the other types of publications on this topic, follow the link: Platelet activating factor.

Journal articles on the topic 'Platelet activating factor'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Platelet activating factor.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Wimberly, H. C., D. O. Slauson, and N. R. Neilsen. "Functional and Biochemical Characterization of Immunologically Derived Equine Platelet-Activating Factor." Veterinary Pathology 22, no. 4 (1985): 375–86. http://dx.doi.org/10.1177/030098588502200413.

Full text

Abstract:

Antigen-specific challenge of equine leukocytes induced the non-lytic release of a platelet-activating factor in vitro. The equine platelet-activating factor stimulated the release of serotonin from equine platelets in a dose-responsive manner, independent of the presence of cyclo-oxygenase pathway inhibitors such as indomethacin. Rabbit platelets were also responsive to equine platelet-activating factor. The release of equine platelet-activating factor was a rapid reaction with near maximal secretion taking place in 30 seconds. Addition of equine platelet-activating factor to washed equine pl

APA, Harvard, Vancouver, ISO, and other styles

2

Zhou, W., M. A. Javors, and M. S. Olson. "Platelet-activating factor as an intercellular signal in neutrophil-dependent platelet activation." Journal of Immunology 149, no. 5 (1992): 1763–69. http://dx.doi.org/10.4049/jimmunol.149.5.1763.

Full text

Abstract:

Abstract The role of platelet-activating factor (PAF) in heterotypic cell to cell interactions in a rabbit neutrophil-platelet mixture model was investigated. Platelets were exposed to each of three chemotactic agonists: PAF, leukotriene B4 (LTB4), or FMLP. Only PAF stimulated aggregation, [3H]serotonin secretion, and cytosolic Ca2+ mobilization in platelets alone. However, platelets were stimulated by LTB4 and FMLP in the presence of neutrophils. This neutrophil-dependent platelet activation was blocked by pretreatment of platelets with PAF receptor antagonists, and was prevented by desensiti

APA, Harvard, Vancouver, ISO, and other styles

3

Perry, Seth W., Jason A. Hamilton, Larry W. Tjoelker, et al. "Platelet-activating Factor Receptor Activation." Journal of Biological Chemistry 273, no. 28 (1998): 17660–64. http://dx.doi.org/10.1074/jbc.273.28.17660.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Welch, Emily J., Ram P. Naikawadi, Zhenyu Li, et al. "Opposing Effects of Platelet-Activating Factor and Lyso-Platelet-Activating Factor on Neutrophil and Platelet Activation." Molecular Pharmacology 75, no. 1 (2008): 227–34. http://dx.doi.org/10.1124/mol.108.051003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

KAWASAKI, Tomio, and Jun-ichi KAMBAYASHI. "Platelet-activating Factor." Japanese Journal of Thrombosis and Hemostasis 2, no. 4 (1991): 274–85. http://dx.doi.org/10.2491/jjsth.2.274.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Kingsnorth, A. N. "Platelet-Activating Factor." Scandinavian Journal of Gastroenterology 31, sup219 (1996): 28–31. http://dx.doi.org/10.3109/00365529609104996.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

McCORMACK, DAVID G., PETER J. BARNES, and TIMOTHY W. EVANS. "Platelet-activating factor." Critical Care Medicine 18, no. 12 (1990): 1398–402. http://dx.doi.org/10.1097/00003246-199012000-00018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Martin, John. "PLATELET-ACTIVATING FACTOR." Lancet 332, no. 8626-8627 (1988): 1486. http://dx.doi.org/10.1016/s0140-6736(88)90956-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Humphreys, Randy F. "PLATELET ACTIVATING FACTOR." Southern Medical Journal 83, Supplement (1990): 2S—2. http://dx.doi.org/10.1097/00007611-199009001-00004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Prescott, S. M., G. A. Zimmerman, and T. M. McIntyre. "Platelet-activating factor." Journal of Biological Chemistry 265, no. 29 (1990): 17381–84. http://dx.doi.org/10.1016/s0021-9258(18)38167-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Lomazova, K. D., A. M. Polyakova, O. S. Astrina, and D. B. Tsukerman. "Platelet activating factor and endotoxin-induced platelet activation." Bulletin of Experimental Biology and Medicine 107, no. 5 (1989): 611–14. http://dx.doi.org/10.1007/bf00841762.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Schulam, P. G., A. Kuruvilla, G. Putcha, L. Mangus, J. Franklin-Johnson, and W. T. Shearer. "Platelet-activating factor induces phospholipid turnover, calcium flux, arachidonic acid liberation, eicosanoid generation, and oncogene expression in a human B cell line." Journal of Immunology 146, no. 5 (1991): 1642–48. http://dx.doi.org/10.4049/jimmunol.146.5.1642.

Full text

Abstract:

Abstract Platelet-activating factor is a potent mediator of the inflammatory response. Studies of the actions of platelet-activating factor have centered mainly around neutrophils, monocytes, and platelets. In this report we begin to uncover the influence of platelet-activating factor on B lymphocytes. Employing the EBV-transformed human B cell line SKW6.4, we demonstrate that platelet-activating factor significantly alters membrane phospholipid metabolism indicated by the incorporation of 32P into phosphatidylcholine, phosphatidylinositol, and phosphatidic acid but not significantly into phos

APA, Harvard, Vancouver, ISO, and other styles

13

Johnson, C. D. "Platelet-Activating Factor and Platelet-Activating Factor Antagonists in Acute Pancreatitis." Digestive Surgery 16, no. 2 (1999): 93–101. http://dx.doi.org/10.1159/000018699.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Yasuda, K., M. Takashima, K. Umesaki, et al. "Platelet activating factor and platelet activating factor acetylhydrolase in uteroplacental circulation." Placenta 15, no. 7 (1994): A94. http://dx.doi.org/10.1016/0143-4004(94)90228-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Summers, James B., Steven K. Davidsen, and George S. Sheppard. "Platelet Activating Factor Antagonists." Current Pharmaceutical Design 1, no. 2 (1995): 161–90. http://dx.doi.org/10.2174/1381612801666220917215816.

Full text

Abstract:

Platelet Activating Factor (PAF) is a D-glycerol-derived phospholipid which is a potent endogenous mediator of inflammation. PAF is synthesized and released by a variety of cell types and elicits its biological activity by interacting with specific G-protein coupled receptors found on platelets, neutrophils, and other inflammatory cells. The physiological consequences of the interaction of PAF with its receptor includes an increase in vascular permeability, hypotension, bronchoconstriction, and platelet and neutrophil aggregation. These biological effects are consistent with the concept that P

APA, Harvard, Vancouver, ISO, and other styles

16

Gomez, Federico P., and Robert Rodriguez-Roisin. "Platelet-Activating Factor Antagonists." BioDrugs 14, no. 1 (2000): 21–30. http://dx.doi.org/10.2165/00063030-200014010-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Koltai, Matyas, David Hosford, Philippe Guinot, André Esanu, and Pierre Braquet. "Platelet Activating Factor (PAF)." Drugs 42, no. 1 (1991): 9–29. http://dx.doi.org/10.2165/00003495-199142010-00002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Koltai, Matyas, and Pierre G. Braquet. "Platelet-activating factor antagonists." Clinical Reviews in Allergy 12, no. 4 (1995): 361–80. http://dx.doi.org/10.1007/bf02802300.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Saunders, R. N., and D. A. Handley. "Platelet-Activating Factor Antagonists." Annual Review of Pharmacology and Toxicology 27, no. 1 (1987): 237–55. http://dx.doi.org/10.1146/annurev.pa.27.040187.001321.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Chung, K. F. "Platelet activating factor revisited." Thorax 52, no. 12 (1997): 1019–20. http://dx.doi.org/10.1136/thx.52.12.1019.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Roudebush, William. "Seminal Platelet-Activating Factor." Seminars in Thrombosis and Hemostasis 33, no. 1 (2007): 069–74. http://dx.doi.org/10.1055/s-2006-958464.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Lee, Tae-Yoon. "Platelet Activating Factor-Acetylhydrolase." Yeungnam University Journal of Medicine 24, no. 2 Suppl (2007): S142–151. http://dx.doi.org/10.12701/yujm.2007.24.2s.s142.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Honda, Z. i., S. Ishii, and T. Shimizu. "Platelet-Activating Factor Receptor." Journal of Biochemistry 131, no. 6 (2002): 773–79. http://dx.doi.org/10.1093/oxfordjournals.jbchem.a003164.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Stafforini, Diana M., Thomas M. McIntyre, Guy A. Zimmerman, and Stephen M. Prescott. "Platelet-activating Factor Acetylhydrolases." Journal of Biological Chemistry 272, no. 29 (1997): 17895–98. http://dx.doi.org/10.1074/jbc.272.29.17895.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Arai, Hiroyuki. "Platelet-activating factor acetylhydrolase." Prostaglandins & Other Lipid Mediators 68-69 (August 2002): 83–94. http://dx.doi.org/10.1016/s0090-6980(02)00023-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Ishii, Satoshi, Takahide Nagase, and Takao Shimizu. "Platelet-activating factor receptor." Prostaglandins & Other Lipid Mediators 68-69 (August 2002): 599–609. http://dx.doi.org/10.1016/s0090-6980(02)00058-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Izumi, Takashi, Tomoko Takano, Haruhiko Bito, et al. "Platelet-activating factor receptor." Journal of Lipid Mediators and Cell Signalling 12, no. 2-3 (1995): 429–42. http://dx.doi.org/10.1016/0929-7855(95)00028-o.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Bevers, Edouard, Theo Lindhout, and Johan Heemskerk. "Platelet Activation and Blood Coagulation." Thrombosis and Haemostasis 88, no. 08 (2002): 186–93. http://dx.doi.org/10.1055/s-0037-1613209.

Full text

Abstract:

SummaryPlatelet activation and blood coagulation are complementary, mutually dependent processes in haemostasis and thrombosis. Platelets interact with several coagulation factors, while the coagulation product thrombin is a potent platelet-activating agonist. Activated platelets come in a procoagulant state after a prolonged elevation in cytosolic [Ca2+]i. Such platelets, e. g. when adhering to collagen via glycoprotein VI, expose phosphatidylserine (PS) at their outer surface and produce (PS-exposing) membrane blebs and microvesicles. Inhibition of aminophospholipid translocase and activatio

APA, Harvard, Vancouver, ISO, and other styles

29

Holub, Bruce J., Diana J. Philbrick, Anwar Parbtani, and William F. Clark. "Dietary lipid modification of renal disorders and ether phospholipid metabolism." Biochemistry and Cell Biology 69, no. 7 (1991): 485–89. http://dx.doi.org/10.1139/o91-072.

Full text

Abstract:

The formation of arachidonic acid derived eicosanoids, including thromboxane A2 and leukotriene B4, as well as platelet-activating factor (1-O-alkyl-2-acetyl-glycerophosphocholine), has been implicated in various renal pathophysiologies. Alteration of the fatty acid composition of membrane phospholipids in platelets, the glomerulus, and inflammatory cells, and of 1-O-alkyl-2-acyl-glycerophosphocholine (platelet-activating factor precursor) can be attained by dietary lipid modifications (e.g., consumption of fish oil containing n – 3 polyunsaturated fatty acids). These changes have been associa

APA, Harvard, Vancouver, ISO, and other styles

30

Karpouza, Angeliki P., and Catherine Vakirtzi-Lemonias. "The platelet-activating factor acetylhydrolase of mouse platelets." Biochimica et Biophysica Acta (BBA) - Biomembranes 1323, no. 1 (1997): 12–22. http://dx.doi.org/10.1016/s0005-2736(96)00178-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Chesney, Carolyn M., D. David Pifer, and Kim M. Huch. "Desensitization of human platelets by platelet activating factor." Biochemical and Biophysical Research Communications 127, no. 1 (1985): 24–30. http://dx.doi.org/10.1016/s0006-291x(85)80120-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

VALONE, F. "Synthesis of platelet-activating factor by human monocytes stimulated by platelet-activating factor." Journal of Allergy and Clinical Immunology 87, no. 3 (1991): 715–20. http://dx.doi.org/10.1016/0091-6749(91)90394-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Duronio, Vincent, Anne Reany, Sandra Wong, Chantal Bigras, and Hassan Salari. "Characterization of platelet-activating factor receptors in porcine platelets." Canadian Journal of Physiology and Pharmacology 68, no. 12 (1990): 1514–19. http://dx.doi.org/10.1139/y90-230.

Full text

Abstract:

Despite a large number of studies describing the properties and effects of platelet-activating factor (PAF), little is known about its receptor structure. The characterization of the PAF receptor from additional cell types and species is important for the design of strategies to purify and characterize the receptor molecule. Porcine platelets were shown to bind PAF with characteristics similar to several other species, based on receptor number, affinity, and the activity of PAF antagonists. We found that the affinity for binding was higher in porcine than in rabbit platelets (Kd = 0.68 ± 0.13

APA, Harvard, Vancouver, ISO, and other styles

34

Montrucchio, G., G. Alloatti, C. Tetta, et al. "Release of platelet-activating factor from ischemic-reperfused rabbit heart." American Journal of Physiology-Heart and Circulatory Physiology 256, no. 4 (1989): H1236—H1246. http://dx.doi.org/10.1152/ajpheart.1989.256.4.h1236.

Full text

Abstract:

This study shows that platelet-activating factor (PAF) is released in significant amounts (10.9 +/- 12.8 ng/min) during the initial reperfusion of the ischemic-isolated rabbit heart. When reperfusion was performed in the presence of autologous rabbit platelets, the electrical and mechanical alterations characteristic of this phase were significantly worsened. These alterations were antagonized by pretreatment of rabbit platelets with a PAF receptor antagonist (SDZ 63-675), suggesting a contribution of PAF released during reperfusion in the cardiac dysfunction. To discriminate whether the effec

APA, Harvard, Vancouver, ISO, and other styles

35

Murphy, WG, JC Moore, and JG Kelton. "Calcium-dependent cysteine protease activity in the sera of patients with thrombotic thrombocytopenic purpura." Blood 70, no. 5 (1987): 1683–87. http://dx.doi.org/10.1182/blood.v70.5.1683.1683.

Full text

Abstract:

Abstract Plasma and serum from patients with thrombotic thrombocytopenic purpura (TTP) can cause activation and aggregation of normal human platelets in vitro. It is possible that this platelet-activating factor contributes to the disease. In this report we describe studies designed to identify the platelet-activating factor in TTP. Platelet activation by sera from 15 patients with TTP was inhibited by leupeptin, iodoacetamide, and antipain but not by phenylmethylsulphonylfluoride, epsilon-aminocaproic acid, soybean trypsin inhibitor, aprotinin, and D-phenylanyl-1-prolyl-1- arginine chlorometh

APA, Harvard, Vancouver, ISO, and other styles

36

Murphy, WG, JC Moore, and JG Kelton. "Calcium-dependent cysteine protease activity in the sera of patients with thrombotic thrombocytopenic purpura." Blood 70, no. 5 (1987): 1683–87. http://dx.doi.org/10.1182/blood.v70.5.1683.bloodjournal7051683.

Full text

Abstract:

Plasma and serum from patients with thrombotic thrombocytopenic purpura (TTP) can cause activation and aggregation of normal human platelets in vitro. It is possible that this platelet-activating factor contributes to the disease. In this report we describe studies designed to identify the platelet-activating factor in TTP. Platelet activation by sera from 15 patients with TTP was inhibited by leupeptin, iodoacetamide, and antipain but not by phenylmethylsulphonylfluoride, epsilon-aminocaproic acid, soybean trypsin inhibitor, aprotinin, and D-phenylanyl-1-prolyl-1- arginine chloromethyl ketone

APA, Harvard, Vancouver, ISO, and other styles

37

Potron, G., E. Petitfrere, and P. Nguyen. "Platelet activating factor and ischemia." Clinical Hemorheology and Microcirculation 13, no. 2 (1993): 155–76. http://dx.doi.org/10.3233/ch-1993-13202.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

O'Neill, C. "Embryo-derived platelet activating factor." Reproduction, Fertility and Development 4, no. 3 (1992): 283. http://dx.doi.org/10.1071/rd9920283.

Full text

Abstract:

Platelet-activating factor (PAF) is secreted by the preimplantation embryo of a number of species. The role of this secretion is yet to be fully elucidated. Evidence to date indicates that it has an important function as an autocrine stimulant of embryonic metabolism, growth and viability. Production of PAF by embryos appears to be severely compromised in vitro. This may be a major cause of reduced embryo viability following embryo culture and it may also help to explain the controversy in the literature regarding the production of PAF by embryos. PAF also alters several aspects of maternal ph

APA, Harvard, Vancouver, ISO, and other styles

39

Greaves, M. W., and M. R. Judge. "Platelet activating factor in psoriasis." British Journal of Dermatology 136, no. 3 (1997): 467. http://dx.doi.org/10.1111/j.1365-2133.1997.tb14968.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

O'NEILL, CHRISTOPHER, MELANIE COLLIER, and DOUGLAS M. SAUNDERS. "Embryo-Derived Platelet-Activating Factor." Annals of the New York Academy of Sciences 541, no. 1 In Vitro Fert (1988): 398–406. http://dx.doi.org/10.1111/j.1749-6632.1988.tb22276.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Tsuda, Makoto, Hidetoshi Tozaki-Saitoh, and Kazuhide Inoue. "Platelet-Activating Factor and Pain." Biological & Pharmaceutical Bulletin 34, no. 8 (2011): 1159–62. http://dx.doi.org/10.1248/bpb.34.1159.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Pałgan, Krzysztof, and Zbigniew Bartuzi. "Platelet activating factor in allergies." International Journal of Immunopathology and Pharmacology 28, no. 4 (2015): 584–89. http://dx.doi.org/10.1177/0394632015600598.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Minhas, B. S., B. A. Ripps, Y. P. Zhu, H. N. Kim, T. H. Burwinkel, and N. Gleicher. "Platelet Activating Factor and Conception." American Journal of Reproductive Immunology 35, no. 3 (1996): 267–71. http://dx.doi.org/10.1111/j.1600-0897.1996.tb00043.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Stafforini, Diana M., Stephen M. Prescott, Guy A. Zimmerman, and Thomas M. McIntyre. "Mammalian platelet-activating factor acetylhydrolases." Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism 1301, no. 3 (1996): 161–73. http://dx.doi.org/10.1016/0005-2760(96)00040-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Barnes, Peter J. "Platelet-activating factor and asthma." Journal of Allergy and Clinical Immunology 81, no. 1 (1988): 152–60. http://dx.doi.org/10.1016/0091-6749(88)90234-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Peters, Ulrike, Wassja Bankova, and Peter Welzel. "Platelet activating factor synthetic studies." Tetrahedron 43, no. 16 (1987): 3803–16. http://dx.doi.org/10.1016/s0040-4020(01)86866-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

BARNES, PETER J. "Platelet Activating Factor and Asthma." Annals of the New York Academy of Sciences 629, no. 1 Advances in t (1991): 193–204. http://dx.doi.org/10.1111/j.1749-6632.1991.tb37976.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Morley, J. "Platelet activating factor and asthma." Agents and Actions 19, no. 1-2 (1986): 100–108. http://dx.doi.org/10.1007/bf01977264.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Karasawa, Ken, Noriko Satoh, Toshio Hongo, Yasuhito Nakagawa, Morio Setaka, and Shoshichi Nojima. "Radioimmunoassay for platelet-activating factor." Lipids 26, no. 12 (1991): 1126–29. http://dx.doi.org/10.1007/bf02536515.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Furukawa, Masayuki, Edward L. Lee, and John M. Johnston. "Platelet-Activating Factor–Induced Ischemic Bowel Necrosis: The Effect of Platelet-Activating Factor Acetylhydrolase." Pediatric Research 34, no. 2 (1993): 237–41. http://dx.doi.org/10.1203/00006450-199308000-00027.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!